F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
Study Confirms F-star’s Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and ActivationCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a cl...
GlobeNewswire · 23h ago
DJ F-star Therapeutics Initiated at Outperform by William Blair
Dow Jones · 3d ago
F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
GlobeNewswire · 04/01 13:00
DJ F-star Therapeutics Says Merck KGaA Exercises Option in Collaboration
Dow Jones · 04/01 12:29
BRIEF-F-Star Therapeutics Announces Third Option Exercised By Merck KGaA, Darmstadt, Germany In Immuno-Oncology Collaboration · 04/01 12:27
Analysts Offer Insights on Healthcare Companies: F-star Therapeutics (FSTX), Outlook Therapeutics (OTLK) and AC Immune SA (ACIU)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on F-star Therapeutics (FSTX), Outlook Therapeutics (OTLK) and
SmarterAnalyst · 04/01 10:16
BRIEF-F-Star Therapeutics Files For Mixed Shelf Of Upto $125 Mln - SEC Filing · 03/31 10:39
HGEN, CLDX, TBLT and TRIB among midday movers
Gainers: Humanigen (HGEN) +81%.Universe Pharmaceuticals (UPC) +70%.SeaChange International (SEAC) +60%.Elite Education Group International (EEIQ) +34%.Cyanotech (CYAN) +34%.Fly Leasing (FLY) +27%.Trinity Biotech (TRIB) +25%.Virpax Pharmaceuticals (VRPX) +2...
Seekingalpha · 03/29 16:37
Humanigen, Universe Pharmaceuticals leads healthcare gainers; Millendo Therapeutics, Orphazyme among major losers
Gainers: Humanigen (HGEN) +98%, Universe Pharmaceuticals (UPC) +82%, EDAP (EDAP) +13%, Biofrontera (BFRA) +13%, Virpax Pharmaceuticals (VRPX) +7%.Losers: Millendo Therapeutics (MLND) -34%, Orphazyme (ORPH) -32%, Celldex Therapeutics (CLDX) -31%, F-star The...
Seekingalpha · 03/29 15:00
F-star Therapeutics EPS misses by $7.92, beats on revenue
F-star Therapeutics (FSTX): FY GAAP EPS of -$9.69 misses by $7.92.Revenue of $11.26M (-60.2% Y/Y) beats by $5.92M.Press Release
Seekingalpha · 03/29 13:17
F-star Therapeutics Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 29, 2021 / F-star Therapeutics Inc (NASDAQ:FSTX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 29, 2021 at 9:00 AM Eastern Time.To listen to the event live or acce...
ACCESSWIRE · 03/29 12:15
F-star Therapeutics 2020 Rev $11.3M >FSTX
F-star Therapeutics 2020 Rev $11.3M >FSTX
Dow Jones · 03/29 12:10
F-star Therapeutics 2020 Loss/Shr $9.69 >FSTX
F-star Therapeutics 2020 Loss/Shr $9.69 >FSTX
Dow Jones · 03/29 12:01
Press Release: F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
Dow Jones · 03/29 12:00
The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week
Biotech stocks reversed course and ended lower in the week ended March 26, drawing inspiration from the broader market weakness. The earnings news flow was confined to micro- and small-cap companies. Five biopharma companies listed their shares on the Nasd...
Benzinga · 03/27 14:40
GME, RAD, CIDM and EVFM among midday movers
Gainers: ProQR Therapeutics (PRQR) +47%.Cellect Biotechnology (APOP) +47%.Houston Wire & Cable (HWCC) +38%.GameStop (GME) +29%.Koss (KOSS) +28%.Cinedigm (CIDM) +28%.F-star Therapeutics (FSTX) +26%.FreightCar America (RAIL) +24%.Polar Power (POLA) +20%.Immu...
Seekingalpha · 03/25 16:40
Cellect Biotechnology, ProQR Therapeutics leads healthcare gainers; Evolus, Rite Aid among major losers
Gainers: Cellect Biotechnology (APOP) +43%, ProQR Therapeutics (PRQR) +33%, Immutep Limited (IMMP) +29%, F-star Therapeutics (FSTX) +24%, Cancer Genetics (CGIX) +13%.Losers: Evolus (EOLS) -24%, Rite Aid (RAD) -24%, Evofem Biosciences (EVFM) -23%, Cyclo The...
Seekingalpha · 03/25 14:59
Bristol-Myers’ win in melanoma described as ‘important' sparking gains in related stocks
Bristol Myers Squibb ([[BMY]] -0.2%) trades marginally lower in the morning hours despite the pre-market announcement of the positive results from relatlimab and Opdivo combo in a Phase 2/3 trial
Seekingalpha · 03/25 14:57
The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 24)
Benzinga · 03/25 11:58
DJ F-star Therapeutics Price Target Announced at $32.00/Share by Laidlaw & Co.
Dow Jones · 03/24 15:59
Webull provides a variety of real-time FSTX stock news. You can receive the latest news about F-star Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About FSTX
F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.